Abliva AB (publ)
OTC: NEVPF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ellen K. Donnelly
- Employees
- 6
- Headquarters
- Lund, Sweden
- IPO year
- 2014
- Market cap
- $45.1M
- Website
- https://abliva.com
Loading NEVPF…
Loading profile data…Frequently asked questions about NEVPF
What does Abliva AB (publ) (NEVPF) do?
Abliva AB (publ) is a pharmaceutical firm focused on developing novel treatments for primary mitochondrial disorders. Its product pipeline features KL1333, currently in Phase 2/3 clinical trials for the long-term management of these conditions. Another compound, NV354, is undergoing preparations for clinical studies, specifically targeting prima...
Where does NEVPF trade?
Abliva AB (publ) (NEVPF) trades on the Other OTC.
What sector is NEVPF in?
Abliva AB (publ) (NEVPF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Abliva AB (publ)?
Ellen K. Donnelly is the chief executive officer of Abliva AB (publ) (NEVPF).
Where is Abliva AB (publ) headquartered?
Abliva AB (publ) is headquartered in Sweden.
Does NEVPF pay a dividend?
Abliva AB (publ) (NEVPF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NEVPF go public?
Abliva AB (publ) (NEVPF) completed its initial public offering in 2014.